

AD_____

Award Number: W81XWH-06-1-0527

TITLE: Establishment of an 'in vitro cell-based system' to assay radiation sensitivity in breast cancer

PRINCIPAL INVESTIGATOR: Gregory Langland, Ph.D.

CONTRACTING ORGANIZATION: University of California
Berkeley, CA 94720

REPORT DATE: May 2008

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 31-05-2008		2. REPORT TYPE Annual		3. DATES COVERED 1 May 2007 - 30 Apr 2008	
4. TITLE AND SUBTITLE Establishment of an 'in vitro cell-based system' to assay radiation sensitivity in breast cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-06-1-0527	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Gregory Langland, Ph.D. Email: glangland@lbl.gov				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California Berkeley, CA 94720				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The purpose of this proposal is to develop an ' <i>in vitro</i> cell-based system' to study radioresistance in sporadic breast cancer. By performing colony formation assays in response to Xray treatment we have shown that there is a wide range of sensitivities to this form of treatment. Interestingly, we have also observed that <i>p53</i> status does not accurately predict response to radiation treatment. Using correlation studies, we have identified novel predictors of IR resistance/sensitivity. We have sensitized two breast cancer cell lines to X-ray treatment by using RNAi-based technology to inhibit Artemis function. In the future, these observations may have a significant clinical impact on the way radiation oncologists treat breast cancer patients.					
15. SUBJECT TERMS Breast cancer, cell culture, radio-sensitivity/resistance, RNAi, DNA repair, X-ray treatment					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	Page
Introduction	4
Body.....	4
Key Research Accomplishments	8
Reportable Outcomes	9
Conclusions	11
References.....	12
Appendices	N/A

Research Objectives:

The overall goal of this research project is to develop an *in vitro* cell culture system to assess the relative radiation sensitivity in a panel of breast cancer cell lines in order to develop a high throughput system to identify novel targets that will further sensitize these cells to X-ray treatment.

Introduction:

It is estimated that over fifty percent of women each year diagnosed with breast cancer will receive radiation treatment. However, it is often not known if the tumors will respond to radio or chemotherapeutic treatment. Radio-therapy also has many side effects that directly affect quality of life such as skin scarring, hair/pigment loss, chronic pain and fatigue. In order to help treat breast cancer patients and give radiation-oncologists a more detailed model of the response of sporadic breast tumors to radiation treatment we proposed to develop an *in vitro* cell culture system that accurately mimics the response of sporadic breast tumors to radiation treatment.

In order to understand how breast tumors respond to radiation it is important to address how radiation works and how breast epithelial cells respond to IR treatment. IR is energy

transmitted in the form of electrons that pass through the cell and cause damage to the DNA in the form of double strand breaks along with other forms of DNA damage. In a normal cell, there are stress response pathways and DNA repair pathways that are activated independent of each other. It is well known that *p53* is responsible for activating genes that stall the cell cycle to allow the DNA to be repaired before entering back into the cell cycle. While this cell is stalled in G_1 or G_0 , the predominant DNA repair pathway activated is the non-homologous end-joining system which is directly responsible for the religation of the DNA double-strand breaks. This pathway is somewhat error-prone and a few nucleotides of sequence may be lost in this process. To add another layer of complexity to this field, the response of cells to X-rays is at least partially cell-type specific. Some




Figure 1: Breast cancer lines vary in their survival rates to IR exposure.

The breast cancer cell lines were divided into two groups based on *p53* status. These plots are based on clonogenic survival and are presented as the mean (+/- s.d.) values from three independent experiments.

cell-types such as lymphoblasts are very sensitive to X-ray exposure and quickly undergo apoptosis. While epithelial cells do not just enter an apoptotic pathway in response to radiation, but are also known to senesce and undergo mitotic catastrophe. Due to the heterogeneity of sporadic breast cancer genomes many of the stress response and DNA repair pathways are either non-functional or aberrant and this would suggest that there will be a range of responses to X-ray treatment.

Results:


Aim 1: To determine the relative IR-sensitivity of 55 human breast tumor and DCIS-derived cell lines as well as normal HMEC cultures.

Measuring the relative radio-sensitivity of the breast cancer cell lines:

Using traditional colony formation assays we have determined the relative sensitivity and resistance to a subset of our breast cancer cell line panel that will allow us to evaluate genes known to predict radio-responses in other cancer types such as *p53* status. More importantly, we can use statistical analyses to identify novel predictors of radio-resistance and sensitivity. Briefly each cell line was plated in either 200 or 600 cells per well in a six-well plate for low doses (0 or 2 Gy) or plated at 1000 or 5000 cells per well for higher doses of X-rays (4 and 6 Gy). The six-well plates were placed back into the incubator for ten to fourteen days for colonies to form. Once stained with crystal violet, the colonies were counted and plotted. These experiments were conducted at least two other times to generate true biological triplicates.

As presented in **Table 1**, there is almost a ten-fold difference in the most IR-sensitive breast

cancer cell line (HBL100) and the most IR resistant cell line tested T47D. Our data also suggests that *p53* status is poorly correlated with response to X-ray treatment. Basal or luminal status of the cell line also does not seem to be an accurate predictor for IR response. Since the Gray laboratory has determined the relative transcript levels of roughly 22,000 genes by use of Affymetrix U133A chip analysis. We decided to



perform simple correlation studies to determine which gene expression profiles are highly correlated

with IR-resistance and sensitivity. Since response to IR is generally a quadratic-linear based-equation the first step in performing our correlation analysis was to convert our survival data into one continuous variable. We converted the curves into a continuous variable by keeping the dosage in Gy constant and the y-axis was converted to log 10 of the percent survival. The slope of this plot was then used as our continuous variable to represent survival. Next we setup our parameters for the Pearson's correlation between the slope generated from the survival data and the relative expression levels of the Affymetrix data. Our only cutoff was to exclude genes that had less than a two-fold change over our sub-panel of sixteen breast cancer cell lines.


TABLE 2

IR-resistance	Chromosomal location	Gene symbol	Subcellular localization	Function	Pearson's correlation
1	17	ATP6V0A1	CELLULAR	ION TRANSPORT	0.79
2	3	PLA1A	CELLULAR	LIPID METABOLISM	0.79
3	9	SYK	NUCLEAR	AKT PATHWAY	0.76
4	19	CLPTM1	CYTOPLASMIC	DEVELOPMENTAL	0.75
5	11	FLJ11848	UNKNOWN	UNKNOWN	0.75
6	15	PML	NUCLEAR	DNA REPAIR	0.74
7	1	ELOVL1	CYTOPLASMIC	LIPID METABOLISM	0.73
8	2	KIAA0436	UNKNOWN	UNKNOWN	0.72
9	11	DPAGT1	CYTOPLASMIC	POST-TRANSLATIONAL MODIFICATION	0.72
10	17	ABCA5	CYTOPLASMIC	MULTIDRUG RESISTANCE	0.71
IR-sensitivity	Chromosomal location	Gene symbol	Subcellular localization	Function	Pearson's correlation
1	2	PPIG	NUCLEAR	RNA SPLICING	-0.77
2	2	FACL3	CYTOPLASMIC	LIPID METABOLISM	-0.77
3	19	NDUFA7	CYTOPLASMIC	MITOCHONDRIAL	-0.76
4		NA	UNKNOWN	UNKNOWN	-0.75
5	16	RBBP6	NUCLEAR	E3 LIGASE	-0.74
6	1	KIAA0485	UNKNOWN	UNKNOWN	-0.73
7	5	RY1	NUCLEAR	UNKNOWN	-0.73
8	21	DYRK1A	NUCLEAR	UNKNOWN	-0.72
9	11	CDKN1C	NUCLEAR	CELL CYCLE	-0.72
10	18	RAB27B	CYTOPLASMIC	VESICLE TRAFFICKING	-0.72

Table 2 depicts the top ten genes whose transcript levels positively correlated with radio-resistance and our top ten genes whose transcript levels negatively correlated with IR-resistance therefore we categorized these genes as being IR-sensitivity genes. Interestingly, in our top ten genes associated with radio-resistance some are genes known to be associated with radio-resistance and others are novel. For example, CLPTM1 is a gene when mutated causes cleft palate but as reported by Folgueira et al with two other genes was able to correctly classify greater than 95% of clinical breast tumor samples in responsiveness to doxorubicin treatment (Folgueira, Carraro et al. 2005). Our number one gene for IR resistance was ATP6VOA1 which is a vacuolar H(+)ATPase.

This is quite interesting since it is well documented in the literature that ouabain inhibition of sodium, potassium pumps sensitizes tumor cells to IR treatment (Lawrence 1988; Verheye-Dua and Bohm 1996; Verheye-Dua and Bohm 1998). Several lipid metabolism genes appeared on our list (PLA1A, ELOVL1 and FACL3) which further supports previous studies that demonstrated inhibition of fatty acid synthesis suppresses HER2 overexpression and increases apoptotic rates (Menendez, Lupu et al. 2004; Menendez, Vellon et al. 2004; Menendez and Lupu 2005) and also suggests a novel function for fatty acid metabolism. ELOVL1 is essential for long chain fatty acid synthesis and is associated with IR resistance, while FACL3 is known to inhibit fatty acid synthesis and ligate acyl-CoAs to fatty acids (Qiao and Tuohimaa 2004) and is associated with IR sensitivity. Many of these candidates warrant more detailed investigation, which is currently being pursued by direct transcript measurement by Panomics Inc. and by siRNA-directed inhibition of these radio-resistance associated genes.

Western Blot Analysis of NHEJ Members- Potential Predictors of IR-Sensitivity.



Since the NHEJ pathway is essential to repair radiation-induced double-strand breaks, we decided to interrogate the relative protein levels of key components of this pathway. As depicted in **Figure 3**, there was little variation in DNA-PK holoenzyme levels which includes DNA-PKcs and the Ku70/80 heterodimer.

However, we did observe significant differences in both XRCC4 and Artemis protein levels. Merel et al. observed differences in XRCC4 in breast cancer cell lines, and we are the first to observe differences in the levels of expression of the Artemis protein (Merel, Prieur et al. 2002). There were also differences in the migration pattern of Artemis strongly suggesting that different splice variants are

expressed in the mammary epithelium or we maybe detecting degradation products. Unfortunately, there was no strong correlation between radio-sensitivity/resistance and the relative protein levels of XRCC4 or Artemis.


Aim 2: To utilize RNAi-based methodologies in order to specifically knock-down key NHEJ genes (Artemis or DNA-PK) to increase IR sensitivity of selected breast cancer cell lines.

RNAi of Artemis in HBL100 and MDAMB231 cell lines increases IR sensitivity

In Aim 2 of this project we have made significant progress by creating stable cell lines from HBL100 and MDAMB231 that express shRNAs targeting the Artemis transcript. We have also generated stable cell lines that expressing a scrambled shRNA directed against AP2. Once these stable lines were generated, we performed semi-quantitative RT-PCR to determine the efficiency of the Artemis transcript knock-downs. As depicted in **Figure 4**, shRNA #1 is more effective at knocking-down Artemis levels than shRNA #2. shRNA-scrambled AP2 had no significant effect on relative Artemis transcript levels. Western blot analysis confirmed our RT-PCR observations depicting that our shRNA constructs are effective at knocking down Artemis expression levels. Survival assays confirm that the reduction of Artemis expression levels increases radiation sensitivity in the two breast cancer cell lines tested.

Key Research Accomplishments:

We have established survival curves to sixteen breast cancer cell lines in response to IR treatment. *p53* status, luminal or basal cell subtype, NHEJ protein levels are all poor predictors of IR sensitivity. Using correlative analysis, we have identified a novel gene set of predictors of IR resistance/sensitivity which will be of interest to radiation oncologists and radiation biologists. We have established RNAi of Artemis increases IR sensitivity in two breast cancer cell lines MDAMB231 and HBL100.



Reportable Outcomes:

By utilizing colony formation assays we have detected up to ten-fold differences of breast cancer cell lines by measuring survival after IR exposure. These differences do not correlate with cell type classification, *p53* status, NHEJ protein levels or overall growth rate. We have identified a gene set that strongly correlates with IR-resistance/sensitivity. Many of these genes have not been previously implicated in radio-resistance/ sensitivity. Finally, two different breast cancer cell lines have been sensitized to IR treatment by knock-down of the Artemis protein.

Future Directions:

In order to test our *in vitro* observations, we are going to an *in vivo* system. By using mouse xenograph studies, we determine if Artemis targeted breast cancer cell lines by both shRNA and siRNAs are more sensitive to IR treatment.

Aim 3: Validation of our *in vitro* cell-based system to assay radiation sensitivity in breast cancer by using mouse xenograph models.

Summary of Aim:

We will use select breast cancer cell lines that readily form tumors in nude mice (MDAMB231 and MCF7) to test the use of lentiviral shRNA constructs and therapeutic DNA repair gene targeting using neutral liposomal small interfering RNA Delivery. These tumors will be irradiated to determine if the inhibition of specific DNA repair genes reduce tumor size *in vivo* after X-ray treatment.

Specific Aim 3:

Xenograph studies of breast cancer cell lines depleted of Artemis and/or DNA-PK by constitutive shRNA expression or by therapeutic DNA repair gene targeting *in vivo* using neutral liposomal small interfering RNA delivery.

Experiment #1:

In the first experiment, we will determine if the parental MDAMB231 breast cancer cell line is more radio-resistant than established cell lines MDAMB231-4 and MDAMB231-5 (shRNA directed towards Artemis) or MDAMB231-shRNA-scrambled AP2 and there relative sensitivities to X-ray exposure.

Statistical considerations:

Since we are hypothesizing a 50% reduction in tumor size as observed *in vitro* (β error=0.2), ten mice for each group will be used as directed by a power analysis. Continuous variables such as tumor size will be analyzed for statistical significance (achieved if $P < 0.05$) with the Student's t test for two group comparisons and ANOVA will be used for multi-group comparisons.

Induction of breast tumors:

Female athymic nude mice (NCr-*nu*) will be purchased from the National Cancer Institute-Frederick Cancer Center. Each of the different cell lines mentioned in the previous paragraph will be

cultured in 10% FBS DMEM. Cells will be harvested by trypsinization and washed with sterile PBS and resuspended to a concentration of 1×10^8 cells/mL. The cells will be injected subcutaneously into the right thigh area of the nude mice. Tumor growth will be monitored by caliper measurements (palpation).

X-ray treatment of xenograph tumors and tumor analysis:


Once tumor diameter reaches 0.5cm^3 , the mice will be anesthetized and provided with lead-based shielding to protect internal organs such as heart, lung, liver and intestines from unwanted radiation exposure. The tumor will be exposed to one acute dose of medium-level X-rays (60kV/10mA) at 2 Gy or 4 Gy and tumor growth will be continued for 15 to 30 more days. These mice will be euthanized and tumors removed and weighed. Student's t test will be used to determine if there is a significant difference in tumor mass between parental and shRNA expressing cell lines.

Experiment #2:

The goal of this experiment will be to utilize siRNAs as radio-therapeutic in our cell culture/xenograph model.

Previous studies demonstrate that ovarian cancer can be reduced by siRNA directed towards the *EphA2* gene combined with paclitaxel treatment (Landen, Chavez-Reyes et al. 2005). These

siRNAs were coated with a neutral liposome technology that has proven to improve *in vivo* targeting efficiency. In pilot experiments, we will also directly inject naked siRNAs and naked liposomes as a negative control.



Experiment #2:

In the second experiment, we will determine if we can reduce tumor size of breast cancer xenographs using DNA repair gene targeting *in vivo* using liposomal small interfering RNA delivery. Specifically, we will generate xenographs as described in Experiment #1 of the parental cell lines MDAMB231 and MCF-7.

Liposomal/siRNA preparation, injection and X-ray exposure:

siRNAs tagged with Alexa 555 (Qiagen) will be coated in the neutral liposome 1,2-dioleoyl-*sn*-glycero-3-phosphatidylcholine (DOPC) by Anil Sood's laboratory at the Texas M.D. Anderson Medical Center, Houston, TX. We will inject these neutral coated liposomes with siRNAs, naked siRNAs (150ug/kg) or empty liposomes directly into the tumor site. Three days after injection, the tumors will be dosed with X-rays as directed by results from Experiment #1 (4 Gy). Mice ($n=10$ per group) will be monitored for adverse effects and tumors will be harvested 3-4 weeks after X-ray treatment. Mouse weight, tumor weight and distribution of the tumor will be recorded. Vital organs will be harvested and necropsies will be performed by a board-certified veterinarian for evidence of tissue toxicity.

Conclusions:

Our *in vitro* results suggest that RNAi targeting of Artemis will sensitize the xenograph tumors to IR treatment. These results would confirm our previous *in vitro* results and provide more evidence that our *in vitro* cell-culture based system to assay radiation sensitivity in breast cancer. We could then perform more rapid screens of other siRNAs or small molecule inhibitors specifically designed to the gene list described in **Table 2** to further sensitize breast tumors to radio- and chemotherapeutic treatments. Additionally, siRNA therapy could also be used to shrink the tumor before debulking therapy and if the tumors are small enough it might be possible in the near future to treat with siRNAs, radio and chemo-therapeutic therapies and eliminate the breast tumor without having to perform invasive surgery or mastectomies.

Materials and Methods:

Cell Culture:

All breast cancer cell lines were kindly provided by the Gray Laboratory or purchased directly from ATCC. Fetal bovine serum, basal medium, trypsin-EDTA and phosphate buffered saline were purchased from JRS Scientific. The cells were cultured at 37° C, 90% humidity supplemented with 5% CO₂.

Colony survival assays:

Cells were de-attached from their dishes by trypsin incubation and counted using a Coulter counter. For each X-ray dose, cells were plated at both 1000 and 5000 cells per well in triplicate. The cells were allowed to attach overnight and were exposed to X-rays using a Pantek X-ray machine at 320kV/10mA. The doses given were 0, 2, 4 and 6 Gy. The cells were placed in the incubator and incubated for ten to fifteen days to allow colonies to form. The colonies were then examined using phase-contrast microscopy to determine if there were approximately fifty cells per colony. The colonies were fixed and stained with a crystal violet solution and counted by hand. The percent survival was calculated using Microsoft Excel and curves subsequently plotted in semi-log scale

Lentiviral small hairpin RNA (shRNA) construct generation:

In order to efficiently knockdown Artemis expression shRNAs were designed according to standard algorithms. The oligos were synthesized by Operon technologies, allowed to anneal and cloned into a modified pENTRY vector. The pENTRY vectors were sequenced to verify the sequence of the shRNAs and propagated in the *E. coli* strain STBL3. LR reactions were performed according to the manufacturer's protocol (Invitrogen) and this allows the transfer of the shRNA into the Lenti-destination vector. These vectors were transfected into HEK293FT cells along with the helper plasmids necessary for lentiviral production. Lentiviral particles were purified using standard centrifugation techniques and stored at -80° C.

Selection of HBL100 and MDAMB231 cells expressing the shRNAs directed against Artemis:

MDAMB231 cells were infected with lentivirus for forty eight hours and then placed under antibiotic selection for two weeks. The stable clones are then analyzed for Artemis expression or lack thereof by western blot analysis. Survival assays were performed on these cell lines according to the methods stated previously.

RNA Preparation and RT-PCR analysis of Artemis and β -actin expression:

Total RNA from cultured cells was isolated using TRIzol LS Reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA). For reverse transcription-polymerase chain reaction (RT-PCR), Im-Prom-IITM Reverse Transcriptase was used according to the supplier's instructions (Promega, Madison, WI). First-strand cDNA was synthesized from 5 μ g of total RNA using both oligodT and random primers and was carried out at 50°C for thirty minutes in 20 μ L reaction. 2 μ L of cDNA was the starting material for Artemis specific primers and β -actin control primers (Bio-chain Institute, Inc., Hayward, CA). PCR reactions were performed according to the manufacturer's PCR protocol (Bio-chain Institute, Inc., Hayward, CA). Briefly, the PCR reaction consisted of a five minute denaturation, followed by 30 cycles of 94°C x 30 sec., 56°C x 30 seconds, 72°C x 30 sec. and a final extension at 72°C for seven minutes. The PCR products were visualized by resolving on a 1% (0.5% TBE) agarose gel with ethidium bromide and visualized under UV light.

References:

- Folgueira, M. A., D. M. Carraro, et al. (2005). "Gene expression profile associated with response to doxorubicin-based therapy in breast cancer." Clin Cancer Res **11**(20): 7434-43.
- Landen, C. N., Jr., A. Chavez-Reyes, et al. (2005). "Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery." Cancer Res **65**(15): 6910-8.
- Lawrence, T. S. (1988). "Ouabain sensitizes tumor cells but not normal cells to radiation." Int J Radiat Oncol Biol Phys **15**(4): 953-8.
- Menendez, J. A. and R. Lupu (2005). "RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells." Int J Mol Med **15**(1): 33-40.
- Menendez, J. A., R. Lupu, et al. (2004). "Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere)." Breast Cancer Res Treat **84**(2): 183-95.
- Menendez, J. A., L. Vellon, et al. (2004). "Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells." Proc Natl Acad Sci U S A **101**(29): 10715-20.
- Merel, P., A. Prieur, et al. (2002). "Absence of major defects in non-homologous DNA end joining in human breast cancer cell lines." Oncogene **21**(36): 5654-9.
- Qiao, S. and P. Tuohimaa (2004). "Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells." FEBS Lett **577**(3): 451-4.
- Verhey-Dua, F. and L. Bohm (1998). "Na⁺, K⁺-ATPase inhibitor, ouabain accentuates irradiation damage in human tumour cell lines." Radiat Oncol Invest **6**(3): 109-19.
- Verhey-Dua, F. A. and L. Bohm (1996). "Influence of ouabain on cell inactivation by irradiation." Strahlenther Onkol **172**(3): 156-61.